-
Zai Lab Q2 and Full-Year 2024 Report Shows Sales Growth and Loss Reduction
•
China-based biotech Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) released its Q2 and full-year 2024 financial report. The company recorded USD 108.5 million in product net sales in Q4 and USD 397.6 million for the full year of 2024, marking a 65% and 50% year-on-year (YOY) increase at constant exchange…
-
Viatris Q4 and Full-Year Results Show Greater China Growth
•
US generics giant Viatris (NASDAQ: VTRS) released its Q4 and full-year 2024 financial results. In the fourth quarter, revenues dropped 7% year-on-year (YOY) to USD 3.515 billion. However, the Greater China region generated USD 522 million in sales after a 2% expansion. For the whole year, company revenues stood at…
-
SciClone Pharmaceuticals Licenses Eisai’s Tasurgratinib for China
•
China-based SciClone Pharmaceuticals Inc. announced a licensing agreement with Eisai Co., Ltd (TYO: 4523), securing exclusive development and commercialization rights to the Japanese firm’s tasurgratinib succinate (E7090) in China. Drug ProfileTasurgratinib, an orally available selective inhibitor of FGFR 1-3, was approved in Japan in September of last year. It is…
-
Fosun Pharmaceutical’s XS-03 Gets NMPA Green Light for CRC Study
•
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a clinical study of its Category 1 chemical drug XS-03. The study will assess the drug’s use in combination with FOLFOX or FOLFIRI plus…
-
Sino Biopharmaceutical and Sciwind Biosciences Partner on CPX102 Development
•
China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced a strategic partnership with compatriot firm Sciwind Biosciences Co., Ltd. The alliance aims to leverage their respective advantageous resources to promote the research and development of CPX102, an interleukin-29 (IL-29) program from Sino Biopharmaceutical. Specifically, the two companies will carry out exclusive licensing…
-
Bayer’s BlueRock Therapeutics Gets Fast Track for OpCT-001 Therapy
•
German pharmaceutical giant Bayer (ETR: BAYN) and its wholly owned subsidiary BlueRock Therapeutics LP announced that they have received Fast Track Designation from the US Food and Drug Administration (FDA) for OpCT-001. The investigational therapy, derived from induced pluripotent stem cells (iPSC), is intended for the treatment of primary photoreceptor…
-
Chipscreen Biosciences’ CS12088 Gets NMPA Clearance for Hepatitis B Study
•
China-based Shenzhen Chipscreen Biosciences Co., Ltd. (SHA: 688321) announced that the National Medical Products Administration (NMPA) has granted clearance to conduct a study of its investigational drug CS12088 in adult patients with chronic hepatitis B. Drug Mechanism and Preclinical DataCS12088 is an HBV nucleocapsid assembly regulator that interferes with the…
-
Hengrui Pharmaceuticals Gets NMPA Green Light for SHR-A2009 Study
•
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that the National Medical Products Administration (NMPA) has approved the initiation of a Phase Ib/II clinical study for its drug candidate SHR-A2009. The study will assess the safety, tolerability, and efficacy of SHR-A2009 as a treatment for advanced solid tumors in…
-
GE Healthcare’s China CEO Yihao Zhang to Retire, Will Song Named Successor
•
US medical device and life sciences giant GE Healthcare Technologies Inc. (NASDAQ: GEHC) announced the retirement of Yihao Zhang, president and CEO of its China operations, effective July 1, 2025. Will Song, a Johnson & Johnson veteran with over 20 years of experience, will join the company on April 1,…
-
Zhongsheng Pharmaceutical’s RAY1225 Gets Green Light for Phase III Study
•
China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) announced that it has received approval in China to conduct a multi-center, randomized, double-blind, placebo-controlled Phase III study of its polypeptide drug candidate RAY1225 in obese and overweight patients. Drug Profile and Previous TrialsRAY1225 is a long-acting glucagon-like peptide-1 (GLP-1) drug with…
-
Akeso Inc. Completes Patient Enrollment for AK138D1 Phase I Study
•
China-based biotech Akeso Inc. (HKG: 9926) announced the completion of patient enrollment in the Phase I clinical study assessing the safety, tolerability, pharmacokinetics, and preliminary efficacy of its AK138D1 in advanced malignant tumors in Australia. Drug ProfileAK138D1, an antibody-drug conjugate (ADC) targeting human epidermal growth factor receptor 3 (HER3), features…
-
CARsgen Therapeutics Administers KJ-C2219 in SLE Patient in IIT
•
China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) announced that it has administered its KJ-C2219 at the starting dose specified in the clinical protocol in the first patient with systemic lupus erythematosus (SLE) in an investigator-initiated trial (IIT). Therapy DetailsKJ-C2219, an allogeneic CAR-T therapy targeting CD19/CD20, was developed via CARsgen’s THANK-u…
-
Adagene Starts Phase II Trial of Muzastotug for Colorectal Cancer
•
China-based Adagene Inc. (NASDAQ: ADAG) announced the initiation of an Investigator-Initiated (IIT) Phase II trial for muzastotug (ADG126) as a neoadjuvant therapy for patients with stage II or stage III colorectal cancer. Drug ProfileMuzastotug is a masked, anti-CTLA-4 SAFEbody that targets a unique epitope of CTLA-4 in regulatory T cells…
-
Shanghai Moyang Biotech’s Aphranel CC Needle Wins NMPA Approval
•
China-based Shanghai Moyang Biotechnology Co., Ltd, an innovation-focused company in nanomedical biomaterials and Class III absorbable implants, announced it has received a Category III medical device license from the National Medical Products Administration (NMPA) for its Aphranel CC needle. The high-end medical aesthetics product is used for subcutaneous injection of…
-
Huadong Medicine’s ADC HDM2005 Granted FDA Orphan Drug Designation for MCL
•
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that its antibody-drug conjugate (ADC) HDM2005 has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of mantle cell lymphoma (MCL). Drug Mechanism and Preclinical ResultsPreclinical studies have shown that after HDM2005 enters the…
-
EpimAb and Medigene Team Up on TCR-TCE Therapy for Immune-Related Diseases
•
EpimAb Biotherapeutics, Inc. and Medigene AG (ETR: MDG1) today announced a strategic collaboration agreement to research and develop T cell receptor (TCR)-mediated T cell engager therapy (TCR-TCE) for the treatment of immune-related diseases, including solid tumors. Partnership DetailsThe partnership integrates the expertise of both companies across multiple targets. Medigene brings…
-
AstraZeneca’s Camizestrant Shows Promise in SERENA-6 Breast Cancer Study
•
UK-based pharmaceutical giant AstraZeneca (NASDAQ: AZN) announced positive interim analysis results from the Phase III SERENA-6 study for its camizestrant, a next-generation oral selective estrogen receptor degrader (SERD) and complete ER antagonist. Study Details and ResultsThe study evaluated switching to camizestrant in combination with a cyclin-dependent kinase (CDK) 4/6 inhibitor…
-
Bayer’s Gadoquatrane Shows Positive Results in Phase III QUANTI CNS Study
•
German pharmaceutical giant Bayer (ETR: BAYN) announced positive results from the Phase III QUANTI CNS study for its gadoquatrane, a gadolinium-based contrast agent (GBCA), in adults with known or suspected pathologies of the central nervous system undergoing contrast-enhanced magnetic resonance imaging (MRI). Study Details and ResultsIn the trials, gadoquatrane was…
-
Ping An Good Doctor Launches AI-Powered Digital Doctor Service
•
China-based Ping An Healthcare and Technology Co., Ltd (HKG: 1833), also known as Ping An Good Doctor, announced the launch of “Ping An Xin Yi,” an AI-powered digital doctor service integrated within its Ping An Health APP. The service offers 24/7 access to AI-assisted health consultations, marking a significant step…
-
Eli Lilly to Establish Four New US Pharma Manufacturing Sites
•
US major Eli Lilly & Co. (NYSE: LLY) announced plans to establish four new pharmaceutical manufacturing sites in the United States. The move aims to boost the company’s domestic medicine production across various therapeutic areas. API Manufacturing and Supply Chain StrengtheningThree of the new sites will focus on manufacturing active…
